DOCSLIB.ORG

Pathkind (By Mankind) Lab Tests Medical Lab Test Price List

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Pathkind (By Mankind) Lab Tests Medical Lab Test Price List Pathkind (By Mankind) Lab Tests Medical Lab Test Price List 2020 217 www.fungalleria.com | [email protected] +91 -571-2400266 Routine Tests Test Code Test Name MRP Offer HM01 Absolute Eosinophil Count (AEC) 120 108 HM02 Absolute Neutrophil Count (ANC) 160 144 MI01 Acid Fast Bacilli (AFB) Smear 180 162 CO01 Activated Partial Thromboplastin Time(APTT) 400 360 BC01 Adenosine Deaminase (ADA) 500 450 MI06 AFB Stain (3 Samples) 420 378 MI02 Albert Stain (Diphtheria) 250 225 BC03 Albumin 100 90 BC04 Alkaline Phosphatase (ALP) 120 108 BC05 Amylase 300 270 PL01 Anemia Profile Basic (CBC, PS, Reticulocyte Count, Iron, UIBC, TIBC, % Saturation, Ferritin) 1000 900 PL23 Ante Natal Profile 1 (HB, Blood Group, BSR, HIV, HBSAG, HCV (Rapid), VDRL, Urine R/M) 800 720 PL02 Ante Natal Profile Basic (CBC, Blood Group, BSR, HIV, HBSAG, HCV (Rapid), VDRL, TSH, Urine R/M) 1000 900 SE34 Anti Nuclear Antibodies (ANA), IFA 2000 1800 SE02 Anti Streptolysin O (ASO), Quantitative 250 225 CP01 Ascitic Fluid Analysis 400 360 BC07 Bilirubin (Total, Direct & Indirect) 170 153 BC08 Bilirubin Direct 140 125 BC09 Bilirubin Total 120 108 CO02 Bleeding Time (BT) & Clotting Time (CT) 160 144 HM03M Blood Group 80 72 BC390 Blood Urea 90 80 BC10 Blood Urea Nitrogen (BUN) 90 80 CL23 CA 125 1200 1080 BC11 Calcium 120 108 BC12 Calcium, 24 Hrs Urine 150 135 FC04 CD4/CD8-Lymphocyte Enumeration Study 2390 2150 CP02 Cerebrospinal Fluid (CSF) Analysis 400 360 SE03 Chikungunya IgM, Rapid Card 970 873 BC13 Chloride 140 125 BC14 Chloride, Urine 190 170 PL04 Coagulation Profile (PT, APTT, BT & CT) 700 630 HM05 Complete Blood Count (CBC) 210 190 SE04 C-Reactive Protein (CRP), Quantitative 350 315 BC16 Creatine Phosphokinase (CPK) 200 180 www.fungalleria.com | [email protected] +91 -7529920063 Test Code Test Name MRP Offer BC17 Creatinine 100 90 BC18 Creatinine Clearance 24 Hrs Urine 500 450 BC19 Creatinine, 24 Hrs Urine 150 135 MI78 Culture Aerobic 750 675 MI85 Culture Aerobic, ET Secretion/Aspirate 550 495 MI81 Culture Aerobic, Pus 550 495 MI82 Culture Aerobic, Vaginal Swab 550 495 MI66 Culture, Body Fluid 550 495 MI32 Culture, CSF 550 495 MI34 Culture, Ear 550 495 MI35 Culture, Eye 550 495 MI39 Culture, RespiratoryIsolation & Identification + Sensitivity 750 675 MI65 Culture, Semen 550 495 MI40 Culture, Sputum 550 495 MI42 Culture, Stool 400 360 MI43 Culture, Throat Swab 550 495 MI44 Culture, Urine 400 360 CY07 Cytology For Malignant Cells 750 675 SE05 Dengue Duo Rapid Test 1150 1035 SE88 Dengue Ns1 Antigen Test 2100 1890 SE90 Dengue Virus IgG Antibodies 1000 900 SE91 Dengue Virus IgM Antibodies 1000 900 PL06 Diabekind (BSF, BSPP, HbA1c, Lipid Screen, MAU, BUN, Creatinine, Urine R/M) 1250 1125 PL05 Diabescreen (BSF, BSPP, HbA1c) 450 405 HM06 Direct Coombs Test (DCT), Whole BloodEDTA 480 432 HM40 DLC (Differential Leucocyte Count) 110 99 BC20 Electrolytes (Na/K/Cl) 300 270 BC21 Electrolytes (Na/K/Cl), Urine 350 315 HM07 Erythrocyte Sedimentation Rate (ESR) 70 63 BC22 Estimated Glomerular Filtration Rate (eGFR) 200 180 CL52 Estradiol (E2) 530 477 BC26 Fasting Plasma Glucose 50 45 CL56 Ferritin 600 540 PL07 Fever Panel- 1 (CBC, ESR, MP Smear, SGPT, WIDAL, Urine R/M) 700 630 PL08 Fever Panel- 2 (CBC, Malaria Antigen, SGPT, WIDAL, Urine R/M, Urine C/S) 1000 900 PL22 Fever Screen (CBC, MP Smear, WIDAL, Urine R/M) 400 360 CY01 Fine Needle Aspiration Cytology (FNAC) 500 450 CL57 Folic Acid 1210 1090 CL62 FT3 (Free Triiodothyronine 3) 370 333 CL63 FT4 & TSH 3rd Gen 430 387 CL64 FT4 (Free Thyroxine 4) 370 333 www.fungalleria.com | [email protected] +91 -7529920063 Test Code Test Name MRP Offer MI03 Fungal Stain 300 270 HM08 G6PD, Qualitative (Glucose-6-Phosphate Dehydrogenase) 650 585 BC24 Gamma-Glutamyl Transferase (GGT) 200 180 BC23 Gestational Glucose Tolerance (GTT- 3) 200 180 BC25 Glucose Challenge Test (GCT) 90 80 BC27 Glucose Post Prandial 50 45 BC28 Glucose Random 50 45 BC29 Glucose Tolerance Test (GTT-2) 150 135 MI04 Gram Stain 170 153 HM09 Haemoglobin (Hb) 70 63 HM31 Haemogram (CBC+ESR) 260 234 HM04 Haemogram (CBC+ESR+PS) 310 280 BC30 HbA1C (Glycosylated Hemoglobin) 400 360 HM10 Hemoglobin & Hematocrit 80 72 SE06 Hepatitis B Surface Antigen (HBsAg), Rapid Card 220 198 SE07 Hepatitis C Antibody (HCV), Rapid Card 220 198 HP54 Histopathology: Large Tissue Biopsy 1330 1197 HP56 Histopathology: Medium Tissue Biopsy 780 700 HP58 Histopathology: Small Tissue Biopsy 640 575 SE08 HIV Antibody, Rapid Card 220 198 BC399 HOMA-IR 920 828 MI67 India Ink 320 288 HM11 Indirect Coombs Test (ICT) Serum 480 430 CL85 Insulin Fasting 800 720 CL87 Insulin PP (Post Prandial) 800 720 BC31 Iron 180 160 BC32 Iron Studies (Iron, TIBC, UIBC, % Saturation) 500 450 BC33 Lactate Dehydrogenase (LDH) 360 324 PL10 Lipid Profile Direct ((Total Cholesterol, Triglycerides, LDL Direct, HDL, VLDL, CHOL/HDL Ratio, 960 864 LDL/HDL Ratio) PL21 Lipid Screen ((Total Cholesterol, Triglycerides, LDL Calculated, HDL, VLDL, CHOL/HDL Ratio, 350 315 LDL/HDL Ratio) Liver & Kidney Profile (Bilirubin Total, Direct & Indirect, SGOT, SGPT, ALP, GGT, LDH, BUN, PL11 Creatinine, BUN/Creatinine Ratio, Uric Acid, Sodium, Potassium, Chloride, Total Protein, Albumin, 1100 990 Globulin, A:G Ratio, Urine Routine) PL12 Liver Function Extended Panel (Bilirubin Total, Direct & Indirect, SGOT, SGPT, ALP, GGT, LDH, 600 540 Total Protein, Albumin, Globulin, A:G Ratio) PL94 Liver Function Test (Bilirubin Total, Direct & Indirect, SGOT, SGPT, AST/ALT Ratio, ALP, Total 400 360 Protein, Albumin, Globulin, A/G Ratio) BC35 Magnesium 500 450 BC36 Magnesium, 24 Hrs Urine 550 495 HM12 Malaria Antigen Detection (Rapid) 130 117 www.fungalleria.com | [email protected] +91 -7529920063 Test Code Test Name MRP Offer HM13 Malarial Parasite (MP) Smear 90 80 MI05 Mantoux / Tuberculin Sensitivity Test 100 90 BC37U24 Microalbuminuria, 24Hrs Urine 550 495 BC37 Microalbuminuria, Spot Urine 550 495 HM14 Microfilaria Detection 200 180 CP03 Miscellaneous Fluid Analysis 400 360 HM23 Osmotic Fragility Test 490 440 CY02 PAP (Papanicolaou) Smear 250 225 CP04 Pericardial Fluid Analysis 400 360 HM15 Peripheral Blood Smear Examination 100 90 BC38 Phosphorus 120 108 BC39 Phosphorus, 24 Hrs Urine 160 144 HM16 Platelet Count 100 90 CP05 Pleural Fluid Analysis 400 360 BC40 Potassium 120 108 BC41 Potassium, Spot Urine 230 207 BC42 Potassium, Urine 230 207 PL13 Pre Operative Extended Panel (CBC, Blood Group, PT INR, APTT, BSR, BUN, Creatinine, HIV, 1450 1305 HBSAG, HCV, TSH) CL103 Prostate Specific Antigen (PSA) Total 750 675 BC43 Protein & Creatinine Ratio Urine 300 270 BC44 Protein, 24 Hrs Urine 200 180 CO03 Prothrombin Time (PT) 250 225 PL09 Renal Profile (Urea, BUN, Creatinine, BUN/Creatinine Ratio, Uric Acid, Sodium, Potassium, 600 540 Chloride, Urine R/M) HM17 Reticulocyte Count 200 180 SE10 Rheumatoid Factor (RF), Quantitative 300 270 CP06 Semen Analysis 300 270 BC45 Serum Ascites Albumin Gradient (SAAG) 380 342 BC06 SGOT / AST 110 99 BC02 SGPT / ALT 110 99 BC46 Sodium 120 108 BC47 Sodium, 24 Hrs Urine 250 225 BC48 Sodium, Spot Urine 250 225 CP07 Stool Occult Blood 100 90 CP08 Stool pH & Reducing Substances 110 99 CP09 Stool Routine & Microscopic Examination 100 90 PL95 Surgical Profile (CBC, BT & CT, Blood Group, BSR, Urea, Creatinine, TSH, HIV, HBsAg, HCV (Rapid) 1000 900 CP10 Synovial/Joint Fluid Analysis 400 360 MB125 TB/ AFB PCR 2000 1800 CL115 Testosterone Free & Total 2000 1800 www.fungalleria.com | [email protected] +91 -7529920063 Test Code Test Name MRP Offer CL116 Testosterone Total 600 540 CL61 Thyroid Profile Free 600 540 HM19 TLC & DLC 190 170 HM39 TLC (Total Leucocyte Count) 110 99 SE210 Torch IgG & IgM Evaluation Panel 2500 2250 SE211 Torch IgG Antibodies 1300 1170 SE212 Torch IgM Antibodies 1300 1170 BC49 Total Cholesterol 120 108 BC50 Total Protein 130 117 BC51 Total Protein & Albumin/Globulin (A/G) Ratio 120 108 CL121 Total T3 (Triiodothyronine) 200 180 CL122 Total T4 (Thyroxine) 200 180 BC52 Triglycerides 200 180 CL123 Triple Marker Test 2700 2430 CL124 Troponin I, Rapid Card 1600 1440 BC53 Troponin T, Rapid Card 780 700 SE252 Typhidot IgG & IgM, Rapid Card 500 450 SE11 Typhidot IgM Rapid Card 350 315 BC54 Urea Nitrogen, 24 Hrs Urine 120 108 BC55 Uric Acid 110 99 BC56 Uric Acid, 24 Hrs Urine 140 125 CP11 Urine Bile Salt & Bile Pigments 50 45 BC413 Urine Calcium & Creatinine Ratio 350 315 CP12 Urine Pregnancy Test (UPT) 150 135 CP13 Urine Routine & Microscopic Examination 70 63 SE12 VDRL 100 90 SE13 VDRL, CSF 100 90 SE232 Viral Markers (HIV, HBsAg, HCV), Rapid Card 700 630 CL131 Vitamin B12 1050 945 CL51 Vitamin Check (Vit D, Vit B12, TSH) 1700 1530 CL132 Vitamin D 25 - Hydroxy 1200 1080 SE14 Widal 130 117 www.fungalleria.com | [email protected] +91 -7529920063 Specialized Tests Test Code Test Name MRP Offer CL01 1,25-Dihydroxy vitamin D 3200 2880 CG01 14Q Rearrangement Blood (ALL, NHL) 4300 3870 CL02 17-Alpha Hydroxyprogesterone 1300 1170 BC344 17-Alpha Hydroxyprogesterone (Neonatal Screen) 250 225 CL03 17-Ketosteroids, Urine 5700 5130 CG02 1P/19Q 9000 8100 SE15 5-Hydroxyindoleacetic Acid (5-HIAA)Urine 24hrs 3500 3150 BC57 Acetone, Serum 1500 1350 BC58 Acetone, Urine (Qualitative) 700 630 CL04 Acetylcholine Receptor (ACHR) Antibody 2170 1950 BC400 Acetylcholine Receptor Blocking Antibodies 9900 8900 BC401 Acetylcholine Receptor ModulatingAntibodies 13200 11800 BC59 Acid Phosphatase (Prostatic) 330 297 CO04 Activated Protein C Resistance (APCR) 3900 3500 CL05 Active Vitamin B12 (Holotranscobalmin) 1600 1440 MB01 ACTN3 Genotyping (Sports Gene) 4800 4300 Acute Hepatitis Marker Profile PL77 2700 (HAV IgM, HBsAg, HBc IgM,
Load more

Recommended publications
  • Dengue–COVID-19 Coinfection: the First Reported Case in the Philippines
    Case Report/Case Series Dengue–COVID-19 coinfection: the first reported case in the Philippines Angyap Saipen,a Bernard Demot,a Lowella De Leona Correspondence to Angyap Lyn Saipen (email: [email protected]) The rainy season in the Philippines is from June to October; this is when the number of dengue cases typically increases. In 2020 during this time, the world was facing the threat of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection. Coronavirus disease 2019 (COVID-19) and dengue viral infections have similar presentations and laboratory findings, including fever and thrombocytopenia, and there have been reports of coinfection with SARS-CoV-2 and arthropod-borne virus. Here, we report a case of SARS-CoV-2–dengue virus coinfection in the Philippines in a female aged 62 years, whose early symptom was fever and who was positive for SARS-CoV-2 and positive for dengue. Early recognition of such coinfection is important so that proper measures can be taken in the management of the patient. engue fever is a mosquito-borne viral infection fever (highest recorded at 39.5 °C), with associated found mostly in tropical climates, including headache (frontoparietal in location, rated 5/10 and Dthe Philippines. The clinical manifestations of bandlike in character) and retro-orbital pain, general- dengue may include high-grade fever, headache, retro- ized body ache, myalgia and arthralgia. There was no orbital pain, muscle and joint pains, and rashes. In associated nausea, vomiting or blurring of vision. The 2019, the Philippines had one of the highest numbers patient had pain over the ankle joints, with no associ- of reported dengue cases among countries in Asia ated warmth or limitation of movement, and no rashes, and South-East Asia.1 According to the World Health cough or dyspnoea.
    [Show full text]
  • VDL Annual Report
    2010 Annual Report Table of Contents ISU VDL Mission Statement .......................................................................................................................... 3 VDPAM Organizational Chart ....................................................................................................................... 4 VDPAM External Advisory Board .................................................................................................................. 5 VDL Faculty List ............................................................................................................................................ 6 VDL Staff List ................................................................................................................................................ 7 New Tests Introduced ................................................................................................................................... 9 2010 Statistical Data ................................................................................................................................... 10 Accessions .............................................................................................................................................. 10 Tests ....................................................................................................................................................... 11 Submission Trends ................................................................................................................................
    [Show full text]
  • 69292/2020/Estt-Ne Hr 5
    5 69292/2020/ESTT-NE_HR Index Sr. No. Particulars Page No. 1 General Billing Rules 2--11 2 Packages Detail 12--23 3 Room Rent 24--25 4 Consultation Charges. 26--32 5 CTVS PACKAGE ROCEDURES 33--35 6 CTVS PEDIATRIC 36--37 7 CATH ADULT PROCEDURES 38--39 8 EP STUDY PACKAGE PROCEDURES 40--41 9 PEDIATRIC CATH PROCEDURES 42--43 10 UROLOGY PROCEDURES 44--46 11 NEPHROLOGY PROCEDURES 47-52 12 VASCULAR SURGERY 53--54 13 GENERAL SURGERY PROCEDURE 55--62 14 NUEROLOGY PROCEDURES 63--67 15 UROLOGY 68--71 16 DENTAL PROCEDURES 72--78 17 DERMATALOGY PROCEDURES 79--82 18 ENT PROCEDURES 83--87 19 NEPHROLOGY 88--89 20 GYNECOLOGY PROCEDURES 90--93 21 LABORATORY TEST CHARGES 94-120 22 ONCOLOGY PROCEDURES 121-126 23 OPTHALMOLOGY PROCEDURES 127-130 24 PULMONOLOGY PROCEDURES 131-134 25 PAIN CLINIC CHARGES 135-136 26 PLASTIC SURGERY 137-141 27 PHYSIOTHERAPY CHARGES 142-144 28 MISC. & OTHER SERVICES 145-148 29 CARDIAC DIAGNOSTIC CHARGES 149-151 30 CT PROCEDURES 152-155 31 MRI PROCEDURES 156-162 32 X RAY PROCEDURES 163-166 33 ULTRASOUND PROCEDURES 167-169 34 DIAGNOSTIC NEUROLOGY 170-172 35 DIANG-HIS 173-174 36 BLOOD BANK 175-176 37 GASTROENTEROLOGY PACKAGES 177-178 38 GASTROENTEROLOGY 179-184 39 TRANSPLANT CHARGES 185-186 0 6 69292/2020/ESTT-NE_HR 40 ORTHOPAEDIC PACKAGES 187-189 41 ORTHOPAEDICS PROCEDURES 190-199 42 MAXILLOFACIAL SURGERY 200-206 43 ONCO SURGERY 207-209 44 INTERVENTIONAL RADIOLOGY & CARDIOLOGY 210-211 45 ANESTHESIA PROCEDURES 212-214 46 PSYCHOLOGY 215-216 1 7 69292/2020/ESTT-NE_HR GENERAL BILLING RULES & GUIDELINES 2 8 69292/2020/ESTT-NE_HR Registration and Admission Charges a) Onetime Registration charges of INR.100/- shall be charged to all new patients coming to Hospital for the first time.
    [Show full text]
  • Severe Dengue Due to Secondary Hemophagocytic Lymphohistiocytosis
    IDCases 8 (2017) 50–53 Contents lists available at ScienceDirect IDCases journal homepage: www.elsevier.com/locate/idcr Case report Severe dengue due to secondary hemophagocytic lymphohistiocytosis: A case study Ujjwayini Ray*, Soma Dutta, Susovan Mondal, Syamasis Bandyopadhyay Apollo Gleneagles Hospitals, 58, Canal Circular Road, Kolkata 70054, West Bengal, India A R T I C L E I N F O A B S T R A C T Article history: Received 17 March 2017 Dengue, transmitted by the mosquito Aedes aegypti affects millions of people worldwide every year. Received in revised form 25 March 2017 Dengue induced hemophagocytic lymphohistiocytosis (HLH) is a serious condition and may prove fatal if Accepted 25 March 2017 not detected early and treated appropriately. Diagnosis of HLH is challenging and usually missed as Available online xxx clinical and laboratory findings are nonspecific. Moreover, the pathophysiology of the systemic inflammatory response syndrome and/or sepsis is remarkably similar to HLH. Secondary HLH following Keywords: infection by the dengue virus is now being increasingly recognized as a cause of severe form of the Bicytopenia disease. We report a case of dengue associated HLH in an otherwise healthy person who deteriorated Dengue during the course of hospitalization. A disproportionately high ferritin level and persistent bicytopenia Hemophagocytic lymphohistiocytosis prompted investigations for HLH. Diagnosis of dengue fever with virus-associated hemophagocytic (HLH) Infection syndrome was established according to the diagnostic criteria laid down by the Histiocyte Society. We discuss the diagnosis and management of this complex case and try to generate awareness about dengue Intravenous immunoglobulin G induced HLH as one of the possible causes for severe manifestations of this infection © 2017 The Authors.
    [Show full text]
  • Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays
    diagnostics Article Flavivirus Cross-Reactivity to Dengue Nonstructural Protein 1 Antigen Detection Assays Li Kiang Tan 1, Wing Yan Wong 1, Hui Ting Yang 1, Roland G. Huber 2 , Peter J. Bond 2,3, Lee Ching Ng 1,4, Sebastian Maurer-Stroh 2,3 and Hapuarachchige Chanditha Hapuarachchi 1,* 1 Environmental Health Institute, National Environment Agency, Singapore 38667, Singapore; [email protected] (L.K.T.); [email protected] (W.Y.W.); [email protected] (H.T.Y.); [email protected] (L.C.N.) 2 Bioinformatics Institute, Agency for Science, Technology and Research, Singapore 138671, Singapore; [email protected] (R.G.H.); [email protected] (P.J.B.); [email protected] (S.M.-S.) 3 Department of Biological Sciences, National University of Singapore, Singapore 117558, Singapore 4 School of Biological Sciences, Nanyang Technological University, Singapore 639798, Singapore * Correspondence: [email protected]; Tel.: +65-65115335; Fax: +65-65115339 Received: 7 November 2019; Accepted: 23 December 2019; Published: 24 December 2019 Abstract: Dengue virus (DENV) and Zika virus (ZIKV) are flaviviruses of public health relevance. Both viruses circulate in the same endemic settings and acute infections generally manifest similar symptoms. This highlights the importance of accurate diagnosis for clinical management and outbreak control. One of the commonly used acute diagnostic markers for flaviviruses is nonstructural protein 1 (NS1). However, false positives due to antigenic cross-reactivity have been reported between DENV and ZIKV infections when using DENV NS1 antigen (NS1 Ag) detection assays in acute cases. Therefore, we investigated the lowest detectable virus titres and cross-reactivity of three commercial dengue NS1 Ag rapid assays and two ELISAs for different flaviviruses.
    [Show full text]
  • Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at Least After 5 Days of Infection
    Research Article Anatomy Physiol Biochem Int J Volume 4 Issue 2- February 2018 Copyright © All rights are reserved by Sudipta Poddar DOI: 10.19080/APBIJ.2017.04.555632 Detection of NS1 Antigen in Serologically Confirmed Dengue Cases at least after 5 Days of Infection Sudipta Poddar* and Amiya Kumar Hati Department of Medical Physiology, Lincoln University College, Malaysia Submission: January 01, 2017; Published: February 09, 2018 *Corresponding author: Sudipta Poddar, Department of Medical Physiology, Lincoln University College, 47301, Petaling Jaya, Malaysia; Email: Abstract Objectives: The objective of this paper is to detect the NS1 antigen beyond 5 days of infection in serologically confirmed dengue cases in whom both NS1 antigen and IgG and IgM antibodies were assessed. Methods: Out of a total of 1037 suspected persons 257 i.e. 24.78% were dengue reactive in 2013 and 2014. Dengue cases were diagnosed in the laboratory from suspected patients by dengue specific IgG, IgM antibodies and NS1 antigen. NS1 antigen and IgG antibodies were monitored in 220 (194+26) suspected dengue cases where interpretation was possible to detect NS1 beyond 5 days of infection. This study of detection of NS1 antigen in serologically confirmed dengue cases at least after 5 days of infection. Results: Among this 220 cases 86 (80+6) were confirmed dengue cases. Out of these 86 cases NS1 antigen was found beyond 5 days of infection in 15 i.e. 17.44%. Conclusion: It would be reasonable to believe that many such cases would be found in the category I where only NS1 was tested. Hence for getting the information on NS1 antigen beyond 5 days all three serological tests (NS1 antigen, IgG and IgM antibodies) should be performed.
    [Show full text]
  • The Point-Of-Care Diagnostic Landscape for Sexually Transmitted Infections (Stis)
    The Point-of-Care Diagnostic Landscape for Sexually Transmitted Infections (STIs) Maurine M. Murtagh The Murtagh Group, LLC 2019 1 Introduction Sexually transmitted infections (STIs) continue to be a significant global public health issue, with an estimated 378 million people becoming ill in 2016 with one of 4 STIs: syphilis, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) (1) . In addition, more than 291 million women have a human papillomavirus (HPV) infection, which is a necessary cause of high grade cervical intraepithelial neoplasia (grade 2 or higher [CIN2+]) (1). This report considers the available and pipeline diagnostics for curable STIs, namely syphilis, CT, NG, TV, and HPV. With some exceptions, the existing diagnostics for these STIs are laboratory-based platforms, which typically require strong infrastructure and well-trained laboratory technicians. In addition, test turnaround time (TAT) is often long, requiring patients to return for test results on a subsequent clinic visit. This, in turn, leads to significant loss to follow-up. Therefore, while these laboratory-based diagnostics are effective, they may not always be suitable for use in resource-limited settings where diagnostic access and delivery are difficult. There are now a variety of tests available for use at or near the point of patient care (POC) for STIs (2). These include a wide range of rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and syphilis, among others, with which it is possible to detect infection using fingerprick blood, or in some cases, oral fluid.1 In addition, other types of POC tests, including simple molecular tests for use in primary healthcare settings, have also become available recently.
    [Show full text]
  • The Point-Of-Care Diagnostic Landscape for Sexually Transmitted Infections (Stis)
    The Point-of-Care Diagnostic Landscape for Sexually Transmitted Infections (STIs) Maurine M. Murtagh The Murtagh Group, LLC 31 May 2018 1 Sexually transmitted infections (STIs) continue to be a significant global public health issue, with an estimated 357 million people becoming ill each year with one of 4 STIs: syphilis, Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Trichomonas vaginalis (TV) (1). In addition, more than 290 million women have a human papillomavirus (HPV), which infection is a necessary cause of high grade cervical intraepithelial neoplasia (grade 2 or higher [CIN2+]) (1). This report considers the available and pipeline diagnostics for curable STIs, namely syphilis, CT, NG, TV, and HPV. With some exceptions, the existing diagnostics for these STIs are laboratory-based platforms, which typically require strong laboratory infrastructure and well-trained laboratory technicians. In addition, test turnaround time is often long, requiring patients to return for test results on a subsequent clinic visit. This, in turn, leads to significant loss to follow-up. Therefore, while these laboratory-based diagnostics are effective, they may not always be suitable for use in resource-limited settings where diagnostic access and delivery are difficult. There are now a variety of tests available for use at or near the point of patient care (POC) for STIs (2). These include a wide range of rapid diagnostic tests (RDTs) for human immunodeficiency virus (HIV), hepatitis C virus and syphilis, among others, with which it is possible to detect infection using fingerprick blood, or in some cases, oral fluid.1 In addition, other types of POC tests, including simple molecular tests for use in primary healthcare settings, have also become available recently.
    [Show full text]
  • Design and Development of Small Molecule Based Biosensors for Detection of Pathogens
    Georgia State University ScholarWorks @ Georgia State University Chemistry Dissertations Department of Chemistry Fall 12-3-2018 Design and development of small molecule based biosensors for detection of pathogens Amrita Das Amrita Das Follow this and additional works at: https://scholarworks.gsu.edu/chemistry_diss Recommended Citation Das, Amrita, "Design and development of small molecule based biosensors for detection of pathogens." Dissertation, Georgia State University, 2018. https://scholarworks.gsu.edu/chemistry_diss/159 This Dissertation is brought to you for free and open access by the Department of Chemistry at ScholarWorks @ Georgia State University. It has been accepted for inclusion in Chemistry Dissertations by an authorized administrator of ScholarWorks @ Georgia State University. For more information, please contact [email protected]. i DESIGN AND DEVELOPMENT OF SMALL MOLECULE BASED BIOSENSORS FOR DETECTION OF PATHOGENS by AMRITA DAS Under the Direction of Suri S Iyer. Ph.D. i ii ABSTRACT Glycans are present on the cell surface of mammalian cells. In Dr. Iyer’s laboratories, we aim to understand the interactions of cell surface glycans with toxins and pathogens at a molecular level and use that information to develop a point of care diagnostics. This thesis primarily focuses on the development of new technologies that could potentially be further developed towards the point of care diagnostics. Chapter 1, the introduction chapter focuses on the biosensors, different recognition molecules, various reporters, techniques, testing parameters used in biosensors and point of care testing (POCT). In chapter 2, the focus is on the development of a novel electrochemical assay that uses repurposed glucose meters for the detection of different analytes.
    [Show full text]
  • Brochure Design 2020 04 15 V2
    D I S C O V E R Rapid Assays Rapid Reliable Expedient T E S T, D I A G N O S E & T R E A T RAPI DAS SAYS ImmunoScience India Pvt. Ltd. Gat No. 41, Village Kusgaon, Shivapur-Velhe Road, Taluka: Bhor, Pune 412205 Maharashtra, India An ISO 9001:2015 and ISO 13485:2016 Company [email protected] OUR NEWEST ADDITION ImmunoQuick Covid-19 IgM/IgG Rapid test for the detection of IgM and IgG antibodies in serum or plasma. Tested by National Institute of Virology, Pune. ImmunoQuick One StepPregnancy Pregnancy Test Device / Dipstick Intended Use : ImmunoQuick Pregnancy, est Pregnancy evice immunoassay for the rapid and visual determination of hCG (human Chorionic D O p Pregnancy T Pregnancy p n e te S te p S ne P D O r e e Pregnancy vic g Gonadotropin) hormone in human urine specimen to aid in the early detection of n e a n c y T e s t pregnancy. Two Formats ISO 9001 : 2015 ISO 13485 : 2016 } Certified Company est 25 One Step Procedure - T cy Pregnancy regnan Dipstick O n Fast - e P tep S - Device (Cassette) and Dipstick (Strip) te p S ne P D O ip r e Pregnancy s g tic n a k n c Duration - Result as early as 30 Seconds y T e One step pregnancy test is a self testing st Clear Results - 5 minutes Easy to use, ISO 9001 : 2015 } Certified Company ISO 13485 : 2016 Early detection - 25 High Sensitivity - Easy to interpret with clear test andSample dark control dropper bands provided with device format.
    [Show full text]
  • Dengue–COVID-19 Coinfection
    COVID-19: Case Report/SeriesArticle type Dengue–COVID-19 coinfection: the first reported case in the Philippines Angyap Saipen,a Bernard Demot,a Lowella De Leona Correspondence to Angyap Lyn Saipen (email: [email protected]) The rainy season in the Philippines is from June to October; this is when the number of dengue cases typically increases. In 2020 during this time, the world was facing the threat of severe acute respiratory syndrome coronavirus 2 (SARS- CoV-2) infection. Coronavirus disease 2019 (COVID-19) and dengue viral infections have similar presentations and laboratory findings, including fever and thrombocytopenia, and there have been reports of coinfection with SARS-CoV-2 and arthropod-borne virus. Here, we report a case of SARS-CoV-2–dengue virus coinfection in the Philippines in a female aged 62 years, whose early symptom was fever and who was positive for SARS-CoV-2 and positive for dengue. Early recognition of such coinfection is important so that proper measures can be taken in the management of the patient. engue fever is a mosquito-borne viral infection fever (highest recorded at 39.5 °C), with associated found mostly in tropical climates, including headache (frontoparietal in location, rated 5/10 and Dthe Philippines. The clinical manifestations of bandlike in character) and retro-orbital pain, general- dengue may include high-grade fever, headache, retro- ized body ache, myalgia and arthralgia. There was no orbital pain, muscle and joint pains, and rashes. In associated nausea, vomiting or blurring of vision. The 2019, the Philippines had one of the highest numbers patient had pain over the ankle joints, with no associ- of reported dengue cases among countries in Asia ated warmth or limitation of movement, and no rashes, and South-East Asia.1 According to the World Health cough or dyspnoea.
    [Show full text]
  • Sd Product Catalog
    SD PRODUCT CATALOG Ordering When you place an order, please inform us of full description, product catalog number, unit size, quantity required including any special instructions with the correct billing and shipping address. Please note that individual products may have different specifications in various markets. Also, some products may not be available in all markets worldwide, only in selected markets. Standard Diagnostics, Inc. 65, Borahagal-ro, Giheung-gu, Yongin-si, Gyeonggi-do, Republic of Korea Tel No. : +82-31-899-2800 Fax No. : +82-31-899-2840 E-Mail : [email protected] Cancellation Any order cancellation should be informed to us within 2 days after placing purchase order. Special custom or large volume orders can not be cancelled at our sole discretion. Pricing Prices will be quoted upon request in US Dollars and are subject to change without prior notice. Quantity discounts are available for bulk. Payment Terms All orders are prepaid unless prior credit arrangements have been made with our Finance Department. All orders are F.O.B. from our factory. Freight charges and insurance charges are the responsibility of the customer. Prices are subject to change without prior notice. Shipping Shipments are made on FCA basis unless otherwise specified. The cost of courier service and special handling if requested shall be the customer’s responsibility. Please specify your shipping requirements when placing your order. Returned Goods Policy No returns shall be accepted without prior approval from SD in the form of an assigned Return Goods Authorization (RGA) Number. To return unused products in error sent to you, please contact us for a RGA Number and further details.
    [Show full text]